| Recruiting | A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Sub Acute Gouty Arthritis | Phase 2 | 2026-03-26 |
| Recruiting | A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Healthy Adult Males in China | Phase 1 | 2026-01-04 |
| Recruiting | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | Phase 3 | 2025-11-21 |
| Active Not Recruiting | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemo Non Small Cell Lung Cancer | Phase 2 | 2025-01-09 |
| Active Not Recruiting | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monothera Non Small Cell Lung Cancer | Phase 2 / Phase 3 | 2024-03-28 |
| Completed | Study of Felzartamab in Healthy Adult Subjects Healthy | Phase 1 | 2024-03-27 |
| Withdrawn | Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma, Second-line Urothelial Carcinoma | Phase 2 | 2023-12-31 |
| Completed | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Hemophagocytic Lymphohistiocytoses | Phase 2 | 2023-04-07 |
| Terminated | A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus Myelodysplastic Syndromes(MDS) | Phase 3 | 2023-03-30 |
| Terminated | A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient Wit Systemic Lupus Erythematosus (SLE) | Phase 1 | 2021-12-30 |
| Terminated | A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-12-30 |
| Active Not Recruiting | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-12-22 |
| Completed | A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Child Pediatric Growth Hormone Deficiency | Phase 3 | 2021-01-25 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Newly Diagnosed Glioblastoma | Phase 2 | 2020-12-31 |
| Active Not Recruiting | A Phase I/II Study of TJ004309 for Advanced Solid Tumor Advanced Solid Tumor | Phase 1 / Phase 2 | 2020-05-09 |
| Completed | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy o Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | Phase 1 / Phase 2 | 2020-03-25 |
| Completed | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refracto Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 3 | 2019-03-27 |
| Completed | Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumord | Phase 1 / Phase 2 | 2019-02-25 |
| Completed | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 2 | 2019-01-28 |